Holen Sie sich die Stockscreener-App
6.655
0.15%
0.065
Handel nachbörslich:
6.60
-0.055
-0.83%
Schlusskurs vom Vortag:
$6.59
Offen:
$6.8
24-Stunden-Volumen:
100.27K
Relative Volume:
0.04
Marktkapitalisierung:
$45.81M
Einnahmen:
$5.21M
Nettoeinkommen (Verlust:
$-26.35M
KGV:
-0.2074
EPS:
-32.0862
Netto-Cashflow:
$-20.84M
1W Leistung:
+13.21%
1M Leistung:
+0.00%
6M Leistung:
+1,003%
1J Leistung:
+2,107%
1-Tages-Spanne:
$6.56
$7.14
1-Wochen-Bereich:
$5.83
$7.30
52-Wochen-Spanne:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
6.655 | 45.36M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Lake Street | Buy |
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics (PSTV) Highlights Economic Benefits of Early D - GuruFocus
Plus Therapeutics Presents Health Economics Study Demonstrating Substantial Healthcare Cost Reduction with CNSide Diagnostic Platform - marketscreener.com
Plus Therapeutics study shows CNSide may cut LM costs by 40% - Investing.com
Plus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual Meeting - Quiver Quantitative
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases - Yahoo Finance
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV Should I Buy - Intellectia AI
PSTV Technical Analysis | Trend, Signals & Chart Patterns | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $12 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Total equity of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net current asset value per share of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total common shares outstanding of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total debt of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net margin % of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics Stockholders Back Directors and Incentive Plan - TipRanks
Number of shareholders of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics (PSTV) Forms Strategic Alliance with Ephemeral Technologies - GuruFocus
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics partners with Ephemeral on AI platform By Investing.com - Investing.com South Africa
Plus Therapeutics, Inc. Cash Flow – DUS:XMP1 - TradingView
Plus Therapeutics partners with Ephemeral on AI platform - Investing.com
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology - The Manila Times
Plus Therapeutics, Inc. Statistics – DUS:XMP1 - TradingView
AI team-up targets faster CNS cancer treatments at Plus Therapeutics - Stock Titan
Plus Therapeutics, Inc. Earnings and Revenue – DUS:XMP1 - TradingView
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ANDREWS RONALD ASBURYmoomoo - Moomoo
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Equity grants for PLUS THERAPEUTICS (PSTV) director An van Es-Johansson - Stock Titan
Plus Therapeutics (PSTV) director receives new option and RSU awards - Stock Titan
Director at Plus Therapeutics (PSTV) receives new equity awards - Stock Titan
Plus Therapeutics (PSTV) director receives new option and RSU grants - Stock Titan
PLUS THERAPEUTICS (PSTV) director awarded new stock options and RSUs - Stock Titan
PLUS Therapeutics (PSTV) CFO receives new stock options and RSU grants - Stock Titan
Plus Therapeutics (PSTV) CEO receives new stock options and 23,834 RSUs - Stock Titan
Headline News about PLUS THERAPEUTICS, Inc.Common Stock - The Chronicle-Journal
Plus Therapeutics reports Q1 loss, raises $15M in offering - Investing.com India
Plus Therapeutics Q1 Loss Narrows, Revenue Declines - Moomoo
Plus Therapeutics (PSTV) Reports Q1 Revenue Exceeding Expectatio - GuruFocus
What Do Plus Therapeutics' Latest Financials Tell Us - Kavout
Plus Therapeutics shareholders approve board elections and key proposals at annual meeting - Investing.com Australia
Plus Therapeutics shareholders approve board elections and key proposals at annual meeting By Investing.com - Investing.com South Africa
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Plus Therapeutics reports Q1 loss, raises $15M in offering By Investing.com - Investing.com South Africa
Plus Therapeutics (PSTV) investors approve directors, pay and 2020 stock plan changes - Stock Titan
PSTV: Net loss narrowed, cash declined, and future funding remains critical amid clinical and commercial progress - TradingView
Plus Therapeutics (PSTV) Q1 2026 loss highlights cash burn and going concern risk - Stock Titan
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - The Manila Times
Plus: Q1 Earnings Snapshot - marketscreener.com
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Plus Therapeutics Inc-Aktie (PSTV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HEDRICK MARC H | Chief Executive Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
499,468 |
| HEDRICK MARC H | Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
339,787 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Nov 04 '25 |
Buy |
0.51 |
20,000 |
10,200 |
68,138 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
159,681 |
0 |
180,106 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
38,323 |
0 |
48,138 |
| Lenk Robert P | Director |
Aug 22 '25 |
Buy |
0.49 |
110,000 |
53,779 |
139,327 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):